Needham & Company Maintains a 'Hold' on Targacept (TRGT); Awaiting Results of Remaining TC-5214 Phase 3 Trials in 1H12

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

February 22, 2012 8:07 AM EST
Get Alerts TRGT Hot Sheet
Price: $0.96 --0%

Rating Summary:
    0 Buy, 6 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Targacept (NASDAQ: TRGT).

Analyst, Alan Carr, said, "Targacept management provided a corporate update in a 4Q11 conference call yesterday after the market close. We believe results of the two remaining TC5214 Phase 3 trials in depression will be announced in the March-May 2012 timeframe. We remain cautious due to negative outcome of the first two trials in 2011 and maintain our rating."

For an analyst ratings summary and ratings history on Targacept click here. For more ratings news on Targacept click here.

Shares of Targacept closed at $6.84 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Needham & Company